Technology

Our targeted ADC platform has demonstrated superior efficacy while limiting toxicities associated with payload delivery in multiple models of disease and inflammation. Our lead program is in IND-enabling studies for the targeted delivery of steroids and leverages decades of understanding of ADCs and steroids, as well as our own discoveries in anti-inflammatory pathways and drug formulation. Data demonstrated safety and efficacy using a significantly lower dose, less frequent dosing, and showed no off-target toxicities. Our unique delivery platform is also being applied to target both innate and adaptive immune cells with different payloads such as small molecules, RNA, and peptides, and can be leveraged to improve the specificity of nanoparticle delivery.